Bayer's Adempas gets insurance coverage in Korea 11 years after approval

21 May 2025 - The pulmonary arterial hypertension medicine Adempas (riociguat) will be covered by national health insurance starting next ...

Read more →

After 9 year wait, Boehringer’s IPF drug Ofev faces generic threat weeks into Korea launch

24 June 2025 - Just two months after German pharma Boehringer Ingelheim secured long-delayed reimbursement for Ofev in Korea, generics ...

Read more →

AbbVie’s Epkinly, Eisai’s Lenvima pass reimbursement review; Janssen’s Tecvayli fails

11 June 2025 - AbbVie Korea's Epkinly (epcoritamab), a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma ...

Read more →

UCB's new psoriasis biologic Bimzelx debuts in Korea with reimbursement

13 June 2025 - Belgium-based UCB's novel psoriasis therapy, Bimzelx (bimekizumab), has officially entered Korea's competitive plaque psoriasis market with ...

Read more →

Gilead’s Trodelvy wins Korean coverage for breast cancer -- too late for some and still off-limits up front

12 June 2025 - It took two years, 100,000 signatures, and a wave of public pressure from patients and doctors. ...

Read more →

MSD Korea wins coverage boost for transplant infection drug Prevymis

4 June 2025 - MSD Korea has won expanded reimbursement for Prevymis (letermovir), extending coverage from 100 to 200 days ...

Read more →

Ipsen’s Cabometyx kidney cancer reimbursement bid collapses in Korea after price talks fail

30 May 2025 - Ipsen Korea’s months-long effort to expand reimbursement for Cabometyx (cabozantinib) has ended in failure, cutting off ...

Read more →

Lilly, Novo Nordisk seek insurance coverage in Korea for diabetes drugs Mounjaro and Ozempic

2 May 2025 - In Korea, Eli Lilly and Novo Nordisk are pushing for national health insurance coverage for their ...

Read more →

Patient group urges quick reimbursement of Besremi for polycythemia vera

7 May 2025 - The Korea Leukemia Patients Organization has called for the reimbursement of Besremi (ropeginterferon alfa-2b), the only ...

Read more →

Pfizer’s ALK lung cancer drug Lorviqua lands first-line reimbursement in Korea

2 May 2025 - Pfizer Korea has secured reimbursement for Lorviqua (lorlatinib) as a first-line treatment for ALK-positive metastatic non-small ...

Read more →

AstraZeneca Korea reapplies for Lynparza reimbursement in prostate cancer

22 April 2025 - AstraZeneca Korea has recently reapplied for health insurance coverage for its PARP inhibitor Lynparza (olaparib) for ...

Read more →

Merck’s Tepmetko wins reimbursement in Korea after 3.5 years, expanding access for lung cancer patients with rare MET mutation

15 April 2025 - Merck’s targeted lung cancer therapy Tepmetko (tepotinib) has finally secured reimbursement from the National Health Insurance ...

Read more →

Pfizer wins Korea nod for paediatric arthritis use of oral JAK inhibitor Xeljanz

7 April 2025 - Pfizer Korea has won national reimbursement for its oral JAK inhibitor Xeljanz (tofacitinib), expanding access to ...

Read more →

Janssen Korea’s Zytiga secures expanded reimbursement for first-line prostate cancer treatment

2 April 2025 - Beginning in April, Janssen Korea's prostate cancer drug Zytiga will be available with prednisolone as a ...

Read more →

GSK Korea's long-acting HIV injection therapy gains insurance benefit

1 April 2025 - GSK Korea said its long-acting injectable HIV-1 combination treatment, Vocabria (cabotegravir 600 mg) and Rekambys (rilpivirine ...

Read more →